Muscle Invasive Bladder Cancer Clinical Trials in Little Rock, Arkansas
9 recruitingLittle Rock, Arkansas
Showing 1–9 of 9 trials
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled101 locationsNCT06510374
Recruiting
Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled75 locationsNCT06545955
Recruiting
Phase 2
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Muscle Invasive Bladder Cancer
Astellas Pharma Global Development, Inc.240 enrolled9 locationsNCT07475806
Recruiting
Phase 1Phase 2
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled20 locationsNCT05710848
Recruiting
Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
Protara Therapeutics131 enrolled66 locationsNCT05951179
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 1
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Urothelial Carcinoma BladderNon Muscle Invasive Bladder CancerNMIBC+3 more
Aura Biosciences55 enrolled17 locationsNCT05483868
Recruiting
Phase 2
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
High-risk Non-muscle Invasive Bladder Cancer
CG Oncology, Inc.325 enrolled65 locationsNCT06567743
Recruiting
Phase 1Phase 2
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734